Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer

New England Journal of Medicine

Volumn 346, Issue 13, 2002, Pages 975-980

  Bergqvist, David ^a   Agnelli, Giancarlo ^b   Cohen, Alexander T ^c   Eldor, Amiram ^d   Nilsson, Paul E ^e   Le Moigne Amrani, Anne ^f   Dietrich Neto, Flavia ^f  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF PERUGIA   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; PLACEBO;

ABDOMINAL CANCER; ADULT; AGED; ARTICLE; BLEEDING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PELVIS CANCER; PHLEBOGRAPHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

ABDOMINAL NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DOUBLE-BLIND METHOD; ENOXAPARIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PELVIC NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; THROMBOEMBOLISM; TIME FACTORS; VENOUS THROMBOSIS;

EID: 0037187892     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa012385     Document Type: Article

References (24)

1. Prevention of venous thromboembolism
2. Deep venous thrombosis: A continuing problem
3. Venous thrombosis and pulmonary embolism: A clinico-pathological study in injured and burned patients
4. A 30-year survey of pulmonary embolism verified at autopsy: An analysis of 1274 surgical patients
5. Incidence of venous thromboembolism verified by necropsy over 30 years
6. Postoperative pulmonary embolism after hospital discharge: An underestimated risk
7. Soll die postoperative thromboembolieprophylaxe auf die nachspitalphase ausgedehnt werden?
8. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
9. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo
10. Prolonged thromboprophylaxis following hip replacement surgery - Results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)
11. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish Prolonged Prophylaxis (DaPP) Study
12. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs. in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: A double-blind, randomized comparison
13. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement
14. Activation of blood coagulation in cancer: Trousseau's syndrome revisited
15. Mechanisms ofhypercoagulation in malignancy and during chemotherapy
16. Maladie thromboembolique et cancer
17. Major thromboembolism and diffuse bleeding after elective general abdominal surgery - Clinical risk factors
18. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment
19. Incidence and prevention of deep venous thrombosis occurring late after general surgery: Randomised controlled study of prolonged thromboprophylaxis
20. Cost-effectiveness of prolonged administration of a low molecular weight heparin for the prevention of deep venous thrombosis following total hip replacement
21. Post discharge clinically overt venous thromboembolism in orthopaedic surgery patients with negative venography - An overview analysis
22. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty - A meta-analysis
23. Building effective prophylaxis of deep vein thrombosis in the outpatient setting
24. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial